NCT03576417View on ClinicalTrials.gov

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

680

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

August 31, 2027

Study Completion Date

September 30, 2027

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Cisplatin

Intravenous

DRUG

Nivolumab

Intravenous

RADIATION

RT

IMRT 66 Gy / 6.5 weeks

Trial Locations (1)

94805

Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
collaborator

For Drug Consulting

OTHER

collaborator

Eurofins

INDUSTRY

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER